Kanghong at A Glance

  • 1996

    Kanghong was founded in 1996

  • 13 Subsidiaries

    with 13 subsidiaries across
    China, US and Israel

  • $ 457 Million

    $457M revenue in 2019


Improving the lives of patients through high quality, innovation, and responsibility.


  • Chinese Social Welfare Enterprises

    We provide access to healthcare for the underserved populations

  • Top 100 in the China's Pharmaceutical Industry

    We are ranked among leading pharmaceutical companies in Mainland China

  • China Industry Awards

    We take pride in our reliable manufacturing capacity

About IOPtima

IOPtima is a fast growing company, focusing on developing minimally invasive and innovative surgical ophthalmic devices. 

IOPtima’s flagship product, the IOPtimate™, is a surgical system for the treatment of Glaucoma, which utilizes CO2 laser technology to significantly reduce internal eye pressure (“IOP”), without penetrating the eye. 

We are an experienced and motivated team. We work towards realizing our vision is of introducing cutting- edge innovation and forefront technologies to the ophthalmic segment. 

IOPtima is a Chengdu Kanghong Pharmaceutical company.